NEULAND LABORATORIES LIMITED Fortifying for a
STRONGER FUTURE
2 0 2 1 - 2 2 A n n u a l R e p o r t
Navigating this Report
Corporate Overview
02 About Us
06 Our Journey - Key Milestones
10 Executive Chairman's Message
12 In conversation with, Vice Chairman & CEO
16 Message from Vice Chairman & Managing Director
18 Value Creation at Neuland
20 Our Strategic Priorities
22 Operational Highlights
26 Financial Highlights
28 Board of Directors
31 Corporate Information
Statutory Report
32 Management Discussion & Analysis
57 Directors' Report
77 Report on Corporate Governance
Quantitative highlights for the year
- 953.2 Crores
Total Revenue
- 144.3 Crores
EBITDA
- 63.5 Crores
Profit after Tax
Financial Statements
103 Standalone
156 Consolidated
Cautionary Statement
Certain statements in this Report relating to our business operations and prospects may be forward-looking statements. These statements can be identified by usage of words such as 'believes', 'estimates', 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'outlook' and other words of similar meaning in connection with a discussion of future operating or financial performance.
These forward-looking statements are dependent on assumptions, data or methods that may be incorrect or imprecise and hence may be incapable of being realised. Such statements are not guaranteed of future operating, financial and other results, but constitute our current expectations based on reasonable assumptions. The Company's actual results could materially differ from those projected in any forward-looking statements due to various future events, risks and uncertainties some of which are beyond our control. We do not assume any obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
To view this report online, please visit:
www.neulandlabs.
com/investors/ financial-reports/annual-reports/
Fortifying for a
STRONGER FUTURE
The global active pharmaceutical ingredient (API) sector is characterised by relentless change. To stay in business and remain competitive, it is important for organisations to continually strengthen themselves, evolve and be ready to respond to opportunities and risk.
At Neuland, the customer is at the centre of everything we do. From understanding their needs thoroughly to going beyond the stated requirements, we strive to ensure that our customers are delighted and remain competitive as our success depends on theirs.
As a global API service provider, ensuring quality APIs time and again is our responsibility and commitment to our customers. During FY 2022, the organisation created a practical framework of six key strategic priorities that will guide us to fortify our business capabilities, drive growth and deliver long-term sustainable value to all our stakeholders.
Aligning our capabilities more closely to meet customer needs, enhancing our manufacturing agility; building stronger project management teams, embedding digitalisation deeper into our business; nurturing and maintaining our leadership succession bench and developing a differentiated product portfolio, our strategic priorities are aimed at making us a stronger organisation.
We are reinforcing our capabilities to drive business agility, better serve our customers and set our organisation on a firmer footing for sustained growth.
We are fortifying for a resilient future.
About
Neuland
WHO WE ARE
Established in 1984, Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solutions provider for the pharmaceutical industry for chemistry-related services. Our expertise extends across generic API manufacturing, advanced intermediates as well as the development and commercialisation of API's for new
WHERE WE ARE BASED
We are headquartered in Hyderabad, India and our manufacturing and research facilities are situated near Hyderabad. Business development offices have been set up in the US, Europe and Japan to strengthen our global collaborations.
OUR MARKETS
We are a reliable manufacturing and development partner to customers in over 80 countries across US, Europe, Japan, APAC, India, MENA and LATAM.
chemical entities (NCEs). Supported by three world-class US FDA and EU GMP compliant manufacturing facilities and complex chemistry capabilities, Neuland has become a trusted partner for innovators as well as generics.
US FDA refers to the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services..
Good manufacturing practice (GMP) describes the minimum standard that a medicines manufacturer must meet in their production processes. The European Medicines Agency (EMA) coordinates inspections to verify compliance with these standards and plays a key role in harmonising GMP activities at European Union (EU) level.
cGMP refers to the Current Good Manufacturing Practice regulations enforced by the FDA.
02
Neuland Laboratories Limited
OUR BUSINESS VERTICALS
Generic Drug Substances (APIs)
Our core business and operational expertise since inception has been the manufacturing of APIs. We have earned the identity of a preferred and reliable API supplier in the pharmaceutical industry primarily due to:
Consistency in product quality
Knowledge and ability to deal with niche chemistry
On-time delivery performance
Custom Manufacturing Solutions
Our deep understanding of complex chemical processes and manufacturing, derived from our proven expertise
in chemical process development to
manufacturing at varied scales, enables us to deliver Custom development and manufacturing solutions. Our offerings span the full range of the pharmaceutical industry's chemistry requirements, from pre-IND through commercial manufacturing. We offer both small- scale clinical trial quantities and full commercial-scale supply with minimal technology transfer timelines. Our manufacturing facilities are compliant with cGMP requirements and meet environment and safety standards.
The R&D facility is approved by the Department of Scientific and Industrial Research (DSIR), Government of India and inspected by the US FDA without any observations.
Annual Report
2021-22
Peptide Capabilities
Our peptide synthesis services include production of peptides from milligrams to multi-kilogram scale by standard sequential chemical peptide synthesis and segment condensation strategies. Neuland has expertise in solution phase synthesis, solid phase synthesis and hybrid technology for complex peptides. We are currently a supplier of high-quality peptide building blocks like Pseudoproline dipeptides and other complex Fmoc building blocks.
OVERVIEW CORPORATE
OUR CORE VALUES
The Neuland Way
We follow a strong set of ethical values, termed 'The Neuland Way', which spurs integrity and motivation among the workforce. An internal cultural survey highlighted that Neuland is a strong, ethical, quality conscious and value-based Company that is committed to making a difference in people's lives. The core of our business is built upon 5 values:
CUSTOMER CENTRICITY | RELIABILITY | ACCOUNTABILITY | |
Reliability whilst delivering the | Being accountable and working | ||
with colleagues to problem solve | |||
Everything we do at Neuland, | promise consistently is our objective. | ||
are an essential part of our role. We | |||
revolves around the customer. From | We ensure we are reliable firstly | by | |
all know that success is not built on | |||
understanding their needs thoroughly | being consistently compliant (cGMP, | ||
a complacent business model. We | |||
to going beyond the stated | EHS, HR, ISMS) both internally and | ||
need to be challenging how we do | |||
requirements, we strive to ensure that | externally. Secondly, to meet our | ||
things and improving them to remain | |||
our customers are delighted with our | customer's requirements and deliver | ||
competitive. Our actions are always | |||
products and services. | on time we bring in place rigorous | ||
in tune with the environment and | |||
project planning and execution. | |||
customer expectations. | |||
OWNERSHIP | OPENNESS & TRANSPARENCY |
At Neuland, we encourage all our colleagues to be part of | Our clear, open and transparent culture at Neuland ensures |
all colleagues communicate and collaborate in the best | |
the solution and tackle all obstacles to complete the task | |
possible way to achieve maximum results. We actively | |
in hand. Part of the reality at Neuland is being aware of | |
encourage the exchange of ideas and thoughts within a HR | |
the opportunity and possibility, then being able to deliver | |
structure that applauds openness. Our project management | |
individually as well as in an open teamwork structure. | |
models give maximum transparency to our customers. | |
STATEMENTS FINANCIAL REPORTS STATUTORY
03
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 08 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 July 2022 05:53:01 UTC.
